218 related articles for article (PubMed ID: 35660001)
1. Nanomedicine for urologic cancers: diagnosis and management.
Li C; Zeng X; Qiu S; Gu Y; Zhang Y
Semin Cancer Biol; 2022 Nov; 86(Pt 2):463-475. PubMed ID: 35660001
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for Combination Urologic Cancer Immunotherapy.
Tian Y; Liu Z; Wang J; Li L; Wang F; Zhu Z; Wang X
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839868
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of nanocarriers for treatment of urologic cancers.
Wang AJY; Yan C; Reike MJ; Black PC; Contreras-Sanz A
Urol Oncol; 2024 Apr; 42(4):75-101. PubMed ID: 38161104
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy in urologic oncology].
Deville JL
Prog Urol; 2011 Nov; 21(11):816-21. PubMed ID: 22032608
[TBL] [Abstract][Full Text] [Related]
6. Immune gene therapy in urology.
Kausch I; Ardelt P; Böhle A; Ratliff TL
Curr Urol Rep; 2002 Feb; 3(1):82-9. PubMed ID: 12084224
[TBL] [Abstract][Full Text] [Related]
7. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
8. Current advances in the application of nanomedicine in bladder cancer.
Zhang C; Zhao J; Wang W; Geng H; Wang Y; Gao B
Biomed Pharmacother; 2023 Jan; 157():114062. PubMed ID: 36469969
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy: new applications in urologic oncology.
Hurwitz ME; Sokhn J; Petrylak DP
Curr Opin Urol; 2016 Nov; 26(6):535-42. PubMed ID: 27584025
[TBL] [Abstract][Full Text] [Related]
10. Molecular therapy in urologic oncology.
Froehner M; Hakenberg OW; Wirth MP
Urol Int; 2007; 79(1):1-7. PubMed ID: 17627159
[TBL] [Abstract][Full Text] [Related]
11. Urologic cancer in Thailand.
Lojanapiwat B
Jpn J Clin Oncol; 2015 Nov; 45(11):1007-15. PubMed ID: 26355159
[TBL] [Abstract][Full Text] [Related]
12. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials.
Xu M; Han X; Xiong H; Gao Y; Xu B; Zhu G; Li J
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446806
[TBL] [Abstract][Full Text] [Related]
13. Strategies for the management of recurrent and advanced urologic cancers. Quality of life.
Herr HW
Cancer; 1987 Aug; 60(3 Suppl):623-30. PubMed ID: 3297289
[TBL] [Abstract][Full Text] [Related]
14. Urologic Oncology Survivorship Guidelines: An Overview of the Evidence and the Current Implementation Gap.
Nguyen DD; Wallis CJD; Fleshner NE; Trinh QD; Klaassen Z; Sayyid RK
Eur Urol Focus; 2023 May; 9(3):431-434. PubMed ID: 36842920
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies.
Sardana R; Mishra SK; Williamson SR; Mohanty A; Mohanty SK
Semin Oncol; 2020 Dec; 47(6):367-379. PubMed ID: 33160642
[TBL] [Abstract][Full Text] [Related]
16. Current progress of nanomedicine for prostate cancer diagnosis and treatment.
Zhao J; Zhang C; Wang W; Li C; Mu X; Hu K
Biomed Pharmacother; 2022 Nov; 155():113714. PubMed ID: 36150309
[TBL] [Abstract][Full Text] [Related]
17. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?
Kurpad R; Kim W; Rathmell WK; Godley P; Whang Y; Fielding J; Smith L; Pettiford A; Schultz H; Nielsen M; Wallen EM; Pruthi RS
Urol Oncol; 2011; 29(4):378-82. PubMed ID: 19576797
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025.
Bertuccio P; Santucci C; Carioli G; Malvezzi M; La Vecchia C; Negri E
Eur Urol Oncol; 2021 Oct; 4(5):677-696. PubMed ID: 34103280
[TBL] [Abstract][Full Text] [Related]
20. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
